| Laramide Resources Ltd (LAM) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$218 |
Laramide Issues Amended AIF Disclosure Westmoreland Project
|
16 Jul 2025 11:15AM |
$0.850 |
$0.770 |
fallen by
9.41%
|
|
| Turaco Gold Limited (TCG) ORDINARY FULLY PAID |
Materials |
$588 |
Application for quotation of securities - TCG
|
16 Jul 2025 11:01AM |
$0.465 |
$0.558 |
risen by
19.89%
|
|
| Lithium Australia Limited1 (LMA) ORDINARY FULLY PAID |
- |
- |
mFund - Distribution - LMA12
|
16 Jul 2025 10:58AM |
n/a |
n/a |
n/a
|
|
| Torque Metals Limited (TOR) ORDINARY FULLY PAID |
Materials |
$271 |
Torque Presentation A New Beginning for Paris Gold
|
16 Jul 2025 10:58AM |
$0.170 |
$0.445 |
risen by
161.76%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$45 |
Prospectus
|
16 Jul 2025 10:57AM |
$0.425 |
$0.108 |
fallen by
74.71%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene Limited is conducting a pro-rata non-renounceable entitlement offer of new shares to existing eligible shareholders.
- The offer seeks to raise capital to support Imugene’s pipeline of immuno-oncology therapies and for general corporate purposes.
- Details about the pricing, eligibility, key dates, and structure of the entitlement offer are provided.
- The company’s clinical programs focus on advancing novel immunotherapies for cancer, leveraging proprietary oncolytic virus and B-cell immunotherapy platforms.
- Funds raised will be used for ongoing clinical trials, research and development, manufacturing, regulatory activities, and working capital.
- The prospectus outlines key risks including clinical trial outcomes, regulatory approval, intellectual property, financial, and market risks.
- Imugene’s recent progress, partnerships, intellectual property status, and management team are described.
- The offer is not underwritten and participation is voluntary for eligible shareholders.
- Legal, taxation, and ASIC compliance information relevant to the offer and shareholders is included.
- Investors are encouraged to read the prospectus in full and seek professional advice before making investment decisions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hazer Group Limited (HZR) ORDINARY FULLY PAID |
Materials |
$98 |
Change of Director's Interest Notice
|
16 Jul 2025 10:56AM |
$0.335 |
$0.365 |
risen by
8.96%
|
|
| Lithium Australia Limited1 (LMA) ORDINARY FULLY PAID |
- |
- |
mFund - Distribution - LMA10
|
16 Jul 2025 10:53AM |
n/a |
n/a |
n/a
|
|
| Lithium Australia Limited1 (LMA) ORDINARY FULLY PAID |
- |
- |
mFund - Distribution - LMA07
|
16 Jul 2025 10:52AM |
n/a |
n/a |
n/a
|
|
| Elixinol Wellness Limited (EXL) ORDINARY FULLY PAID |
Consumer Staple |
$3 |
Appendix 3Y - Natalie Butler - Late Lodgement
|
16 Jul 2025 10:51AM |
$0.017 |
$0.007 |
fallen by
58.82%
|
|
| Lithium Australia Limited1 (LMA) ORDINARY FULLY PAID |
- |
- |
mFund - Distribution - LMA06
|
16 Jul 2025 10:50AM |
n/a |
n/a |
n/a
|
|
| Lithium Australia Limited1 (LMA) ORDINARY FULLY PAID |
- |
- |
mFund - Distribution - LMA04
|
16 Jul 2025 10:49AM |
n/a |
n/a |
n/a
|
|
| MPR Australia Limited (MPR) ORDINARY FULLY PAID |
Financials |
$2 |
Chairman's address to shareholders
|
16 Jul 2025 10:49AM |
$0.009 |
$0.005 |
fallen by
44.44%
|
|
| Lithium Australia Limited1 (LMA) ORDINARY FULLY PAID |
- |
- |
mFund - Distribution - LMA01
|
16 Jul 2025 10:49AM |
n/a |
n/a |
n/a
|
|
| New World Resources Limited (NWC) ORDINARY FULLY PAID |
Materials |
- |
TOV: NWC Panel Receives Review Application
|
16 Jul 2025 10:46AM |
$0.066 |
$0.067 |
risen by
2.29%
|
|
NWC - Price-sensitive ASX Announcement
Full Release
Key Points
- NWC Panel received a review application from shareholder TOV on 19 March 2024.
- The application challenges previous decisions relating to New World Resources Limited.
- Concerns involve disclosure adequacy and protection of shareholder interests.
- Panel review process has been initiated in response to TOV’s concerns.
- Relevant parties have been invited to make submissions to the Panel.
- Review will follow established procedural guidelines to ensure fairness.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Life360 Inc (360) CDI 3:1 FOREIGN EXEMPT XNGS |
Information Technology |
$3,814 |
SEC Form 4
|
16 Jul 2025 10:44AM |
$34.980 |
$21.190 |
fallen by
39.42%
|
|
| Perpetual Credit Income Trust (PCI) ORDINARY UNITS FULLY PAID |
Financials |
$800 |
PCI Monthly Investment Report- June 2025
|
16 Jul 2025 10:41AM |
$1.185 |
$1.095 |
fallen by
7.59%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$45 |
Imugene Capital Raising Presentation
|
16 Jul 2025 10:40AM |
$0.425 |
$0.108 |
fallen by
74.71%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene Limited is undertaking a capital raising via placement and rights issue to fund its immuno-oncology pipeline.
- The company's pipeline includes multiple clinical and preclinical programs focused on innovative cancer immunotherapies.
- Key assets include HER-Vaxx, PD1-Vaxx, CF33 (VAXINIA & CHECKvacc), and other next-generation oncology candidates.
- Funds raised will support ongoing clinical trials, preclinical studies, and operational expenses.
- Imugene reports strong progress in several clinical trials, including HER-Vaxx (gastric cancer), PD1-Vaxx (non-small cell lung cancer), and the CF33 programs (solid tumours).
- The company has achieved significant regulatory and clinical milestones and anticipates several near-term catalysts.
- Management highlights a robust intellectual property portfolio and multiple opportunities for commercial partnerships.
- Imugene has outlined a clear pathway for value creation through the development and commercialization of its products.
- The presentation details the structure, terms, and expected proceeds from the capital raising activities.
- Imugene remains committed to advancing its mission to develop novel treatments that improve patient outcomes in oncology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$585 |
Final Distribution for 30 June 2025
|
16 Jul 2025 10:39AM |
$3.140 |
$2.630 |
fallen by
16.24%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$45 |
Proposed issue of securities - IMU
|
16 Jul 2025 10:39AM |
$0.425 |
$0.108 |
fallen by
74.71%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$45 |
Proposed issue of securities - IMU
|
16 Jul 2025 10:36AM |
$0.425 |
$0.108 |
fallen by
74.71%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$45 |
Imugene Completes $22.5M Placement and c.$15M SPP
|
16 Jul 2025 10:36AM |
$0.425 |
$0.108 |
fallen by
74.71%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene completed a $22.5M placement and approximately $15M via Share Purchase Plan (SPP).
- Proceeds will be used to advance clinical trials for Imugene’s immunotherapy candidates.
- The capital raising received strong support from both institutional and retail investors.
- Funds will support ongoing and future clinical programs, operational expansion, and general corporate activities.
- The announcement reiterates Imugene’s commitment to developing innovative immunotherapies for cancer.
- Details are provided on the allocation of shares, pricing, and the closing of the SPP.
- Recent board and operational updates are included, highlighting strategic priorities.
- The company expresses gratitude to shareholders for their continued support and participation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hawsons Iron Ltd (HIO) ORDINARY FULLY PAID |
Materials |
$18 |
Proposed issue of securities - HIO
|
16 Jul 2025 10:31AM |
$0.021 |
$0.014 |
fallen by
33.33%
|
|
| Plato Income Maximiser Limited (PL8) ORDINARY FULLY PAID |
Financials |
$1,044 |
Net Tangible Asset Backing
|
16 Jul 2025 10:26AM |
$1.400 |
$1.395 |
fallen by
0.36%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$585 |
Update - Dividend/Distribution - OPH
|
16 Jul 2025 10:22AM |
$3.120 |
$2.630 |
fallen by
15.71%
|
|
| Beacon Minerals Limited (BCN) ORDINARY FULLY PAID |
Materials |
$315 |
Near Surface Laterite Mineralisation Identified at Iguana
|
16 Jul 2025 10:18AM |
$1.100 |
$2.810 |
risen by
155.45%
|
|
BCN - Price-sensitive ASX Announcement
Full Release
Key Points
- Beacon Minerals Limited identified near surface laterite mineralisation at the Iguana prospect.
- The mineralisation contains elevated nickel, cobalt, and scandium values.
- Aircore drilling confirmed broad zones of mineralisation, open in several directions.
- Further drilling and systematic sampling are planned to better define mineralisation.
- The project is part of the Jaurdi Gold Project in Western Australia.
- Beacon is expanding exploration efforts into battery metals.
- Existing infrastructure and project experience at Jaurdi will be leveraged for new exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
